US FTC orders Illumina to divest cancer detection test maker Grail

to divest cancer diagnostic test maker Grail, finding that its ownership would stifle competition in the U.S. market for cancer tests.

Judge Michael Chappell, an administrative law judge at the agency, ruled last year that the $7.1 billion acquisition of Grail would not hurt competition. The FTC staff appealed the decision to agency leadership. The agency has expressed concern that Illumina, the dominant provider of DNA sequencing of tumors and cancer cells that help match patients with the best treatment option, might raise prices or refuse to keep selling to rivals of Grail, which is seeking to market a powerful test to diagnose many kinds of cancer from a single blood test, known as liquid biopsy.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FTC Rejects Illumina’s $7 Billion Deal for Cancer-Test Developer GrailThe FTC rejected Illumina’s $7 billion deal for Grail, saying the combination would hurt competition for cancer-detection tests while raising prices Awesome! We finally have people at FTC doing what it takes to preserve competition. Biz school grads will now have to figure out how to make things work in truly competetive markets. The long run benefits of this new dynamic are so valuable. 🎉🎉🥳🪅🪅🥳🥳🥳🥳🥳
Source: WSJ - 🏆 98. / 63 Read more »

FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer GrailThe decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.
Source: CNBC - 🏆 12. / 72 Read more »